Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
September 25, 2024 16:01 ET
|
Abivax
Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease...
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month
September 25, 2024 08:30 ET
|
PRISM MarketView
PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech Innovation
September 24, 2024 11:09 ET
|
Tevogen Bio Inc
WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
Impulse Dynamics Expands Executive Leadership Team
September 24, 2024 09:00 ET
|
Impulse Dynamics
Marlton, NJ, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Impulse Dynamics plc, a global medical device company dedicated to improving the lives of people with heart failure, announced new leadership...
Tersa Earth and Silica-X Sign MoU to Revolutionize Mining and Waste Management with AI-Powered Biotech and Zero-Waste Solutions
September 24, 2024 09:00 ET
|
Tersa Earth Innovations Inc
NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Fresh off its recognition as a Top Innovator in the World Economic Forum’s (WEF) Sustainable Mining Challenge, Tersa Earth Innovations Inc. announces...
YPrime Recognized as Trailblazer in Patient Engagement by Everest Group
September 24, 2024 08:42 ET
|
Y-Prime, LLC
YPrime has been recognized as a Trailblazer in patient engagement by Everest Group for its innovative solutions that enhance clinical trial participation.
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)
September 24, 2024 08:00 ET
|
Araris Biotech
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
September 24, 2024 08:00 ET
|
Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
September 24, 2024 01:00 ET
|
Biogen Inc.
Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary...